Psoriasis and Skin Clinic, Melbourne, Australia.
2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2 Suppl 3):65-72.
Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.
板层状鱼鳞病 (LI) 是一组遗传方式为常染色体隐性遗传的角化异常疾病,其发病率约为每 30 万活产儿中有 1 例。目前,针对该病特征性的大而深褐色鱼鳞状斑块的治疗仍然具有挑战性。本研究旨在评估 Michaels® 皮肤护理产品治疗 LI 的疗效和耐受性。进行了一项多中心欧洲前瞻性研究,纳入了 10 例(3 名女性/7 名男性)板层状鱼鳞病患者,年龄 38-54 岁(平均年龄:46 岁)。既往每位患者均接受过保湿剂加其他不同的全身治疗,如皮质类固醇、环孢素 A 或维 A 酸。所有患者均接受 Michaels® 产品系列治疗,包括局部和口服草药补充剂。局部治疗使用清洁剂凝胶、激活剂配方和软膏。口服药物为 PSC 200、PSC 400 和 PSC 900。治疗开始后 3 周内,皮肤改善情况可见,包括鳞屑减少、皲裂减轻、红斑和瘙痒减轻,角化过度板变薄。治疗 12-15 周后,大部分鳞屑和斑块已脱落,皮肤颜色恢复正常。可见毛发、睫毛和眉毛生长。指甲部分缓解,甲下过度角化减轻。未观察到不良反应。我们的患者在 14 周的治疗内表现出了出色的症状缓解,随后每季度进行持续定期评估。结果表明,Michaels® 产品系列是 LI 的有效且安全的治疗选择。